TetraLogic Pharmaceuticals Corporation (TLOG)

0.0000 -0.0001 (-99.00%) 收市：11:14AM EDT

TetraLogic Pharmaceuticals Corporation

343 Phoenixville Pike
Malvern, PA 19355
United States
610 889 9900
https://www.tetralogicpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 29

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yigong Shi Ph.D.	Co-Founder	無	無	1969
Sarah E. Frew	Director of Business & Commercial Development	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

公司管治

截至 無 止，TetraLogic Pharmaceuticals Corporation 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。